Abstract
Dual antiplatelet therapy with aspirin and oral P2Y12-receptor inhibitors prevents ischemic events in patients undergoing Percutaneous Coronary Intervention (PCI). However, oral administration of antiplatelet drugs cause delay of onset of platelet inhibition in P2Y12-inhibitor naïve patients. Cangrelor is a novel P2Y12-receptor inhibitor which is administrated intravenously and thus allows immediate antiplatelet inhibition during PCI. Due to its unique pharmacokinetics with fast onset of platelet inhibition and very short plasma half-life it allows effective and controllable periprocedural platelet inhibition. It could reduce short-term ischemic events in large randomized clinical trials. The present article reviews the available evidence and application on cangrelor use in clinical practice.
Keywords: Cangrelor, P2Y12-receptor inhibitors, platelet inhibition, coronary artery disease, acute coronary syndrome, percutaneous coronary intervention.
Graphical Abstract
Current Vascular Pharmacology
Title:What is the Role of Cangrelor in Patients Undergoing PCI?
Volume: 16 Issue: 5
Author(s): Michal Droppa and Tobias Geisler*
Affiliation:
- Department of Cardiology and Cardiovascular Medicine, University Hospital of Tubingen, Tubingen,Germany
Keywords: Cangrelor, P2Y12-receptor inhibitors, platelet inhibition, coronary artery disease, acute coronary syndrome, percutaneous coronary intervention.
Abstract: Dual antiplatelet therapy with aspirin and oral P2Y12-receptor inhibitors prevents ischemic events in patients undergoing Percutaneous Coronary Intervention (PCI). However, oral administration of antiplatelet drugs cause delay of onset of platelet inhibition in P2Y12-inhibitor naïve patients. Cangrelor is a novel P2Y12-receptor inhibitor which is administrated intravenously and thus allows immediate antiplatelet inhibition during PCI. Due to its unique pharmacokinetics with fast onset of platelet inhibition and very short plasma half-life it allows effective and controllable periprocedural platelet inhibition. It could reduce short-term ischemic events in large randomized clinical trials. The present article reviews the available evidence and application on cangrelor use in clinical practice.
Export Options
About this article
Cite this article as:
Droppa Michal and Geisler Tobias*, What is the Role of Cangrelor in Patients Undergoing PCI?, Current Vascular Pharmacology 2018; 16 (5) . https://dx.doi.org/10.2174/1570161116666180117105834
DOI https://dx.doi.org/10.2174/1570161116666180117105834 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PiWi RNA in Neurodevelopment and Neurodegenerative Disorders
Current Molecular Pharmacology Exploring the Potential of NO-Independent Stimulators and Activators of Soluble Guanylate Cyclase for the Medical Treatment of Erectile Dysfunction
Current Pharmaceutical Design Harvesting New Therapeutic Avenues with Stem Cell Applications
Current Neurovascular Research Therapeutic Potential of Targeting Protease Activated Receptors in Cardiovascular Diseases
Current Pharmaceutical Design Mesenchymal Stem Cells as Mediators of Neural Differentiation
Current Stem Cell Research & Therapy The GLUTs Family - Lessons from Transgenic Mice
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Development of Small Molecule Non-peptide Formyl Peptide Receptor (FPR) Ligands and Molecular Modeling of Their Recognition
Current Medicinal Chemistry Women’s Ginseng (Angelica sinensis): An Ethnopharmacological Dossier
Current Traditional Medicine Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review
Recent Patents on Biotechnology Cardiac Fat as New Diagnostic Tool and Potential Therapeutic Target for Obesity Management and Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Natural Products to Anti-trypanosomal Drugs: An Overview of New Drug Prototypes for American Trypanosomiasis
Cardiovascular & Hematological Agents in Medicinal Chemistry Pulmonary Complications After Congenital Heart Surgery
Current Respiratory Medicine Reviews Biomedical Applications of Superparamagnetic Nanoparticles in Molecular Scale
Current Organic Chemistry Neuropeptide Y Induces Cardiomyocyte Hypertrophy <i>via</i> Attenuating miR-29a-3p in Neonatal Rat Cardiomyocytes
Protein & Peptide Letters Patented Aptamers for C-Reactive Protein Detection: A Review About their Use in Clinical Diagnostics
Recent Patents on DNA & Gene Sequences Cardiovascular Alterations After Spinal Cord Injury: An Overview
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Antithrombotic / Antiplatelet Therapy in Patients with Stable Coronary Artery Disease and After Acute Coronary Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Radiolabeled Compounds in Diagnosis of Infectious and Inflammatory Disease
Current Pharmaceutical Design Theoretical and Evidence-Based Benefit of Afterload Reduction in the Postoperative Pediatric Heart
Current Vascular Pharmacology Oxidative Stress in the Hypothalamus: the Importance of Calcium Signaling and Mitochondrial ROS in Body Weight Regulation
Current Neuropharmacology